Arbutus Biopharma Cp (ABUS)

$2.80 0.15 (4.93%)

11:03 EDT ABUS Stock Quote Delayed 30 Minutes

ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

More Articles

Volume:

Previous Close -

Market Cap 277.16M

PE Ratio -6.35

EPS -0.44

Volume (Avg. Vol.) 130,032

Day's Range $2.79 - $2.96

52-Week Range $1.69 - $3.29

Dividend & Yield N/A (N/A)

ABUS Stock Predictions, Articles, and Arbutus Biopharma Cp News

From InvestorPlace
From the Web

ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today

By William White, InvestorPlace Writer Dec 1, 2021

Arbutus Biopharma (ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (MRNA).

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Nov 8, 2021

Welcome back, trader! We're starting off the week strong with a dive into the biggest pre-market stock movers for Monday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Sep 10, 2021

We're back at it again with one last day of trading this week and we're kicking it off with Friday's biggest pre-market stock movers.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Jun 28, 2021

Good morning! Let's get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!

Seattle Genetics, Inc. (SGEN) Leads 10 Notable Investor Filings

By Fintel May 18, 2017

13G and 13D filings are windows into activist investor activity. We look at Seattle Genetics, Inc. (SGEN) at 9 other actions

Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M (NASDAQ:ABUS)

From Seeking Alpha Feb 29, 2024

Arbutus Biopharma reports lower revenue in 2023, primarily due to a decrease in license agreement recognition and sales decline.

Arbutus Biopharma stock gains after Markman hearing on Thursday in Moderna dispute

From Seeking Alpha Feb 9, 2024

Arbutus Biopharma&#39;s stock jumped 8% following positive developments in its vaccine patent dispute with Moderna, a biotechnology company.

Arbutus stock lower after FDA snub for Alnylam drug

From Seeking Alpha Oct 9, 2023

The FDA rejection of Alnylam's amyloidosis therapy impacts Arbutus Biopharma, which has a licensing deal with the company for the product. Read more here.

3 Stocks to Buy For the COVID Resurgence

From MarketBeat Sep 6, 2023

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

Why Arbutus Biopharma Stock Is Sinking Today

From The Motley Fool Apr 25, 2023

After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.

Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)

From TipRanks Nov 14, 2022

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Arbutus Biopharma (ABUS – Research Report) on November 9 and set a price target of $4.00. Th...

ADVERTISEMENT